Abstract
Chordomas are rare malignant tumors arising in bone of the spheno-occiput, sacrum, and vertebral column which can cause neurological deficit. Current management of chordoma involves safe resection followed by radiation therapy. However, surgical resection is often subtotal and chordoma often recurs despite optimal therapy. Despite years of effort, effective adjuvant therapy for denovo, recurrent and metastatic chordoma are absent and 5-year survival is at best 65%. While no chemotherapeutic agent has been demonstrated to be effective against chordoma in vivo, a greater understanding of the genetics and molecular biology of chordoma is opening up avenues of investigation towards the rational development of targeted therapies. Although enthusiasm for the use of already established or new investigational agents will increase with greater understanding of chordoma biology, laboratory studies of these agents are important prior to incorporation into clinical human trials. The authors review the current state of knowledge regarding chordoma and offer insight into potential new therapies for this rare and challenging tumor.
Similar content being viewed by others
References
McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM (2001) Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control 12:1–11
Dorfman HD, Czerniak B (1995) Bone cancers. Cancer 75:203–210
Eriksson B, Gunterberg B, Kindblom LG (1981) Chordoma. A clinicopathologic and prognostic study of a Swedish national series. Acta Orthop Scand 52:49–58
Higinbotham NL, Phillips RF, Farr HW, Hustu HO (1967) Chordoma. Thirty-five-year study at Memorial Hospital. Cancer 20:1841–1850
Crockard HA, Steel T, Plowman N, Singh A, Crossman J, Revesz T, Holton JL, Cheeseman A (2001) A multidisciplinary team approach to skull base chordomas. J Neurosurg 95:175–183. doi:10.3171/jns.2001.95.2.0175
Cho YH, Kim JH, Khang SK, Lee JK, Kim CJ (2008) Chordomas and chondrosarcomas of the skull base: comparative analysis of clinical results in 30 patients. Neurosurg Rev 31:35–43. doi:10.1007/s10143-007-0099-z (discussion 43)
Colli B, Al-Mefty O (2001) Chordomas of the craniocervical junction: follow-up review and prognostic factors. J Neurosurg 95:933–943. doi:10.3171/jns.2001.95.6.0933
Forsyth PA, Cascino TL, Shaw EG, Scheithauer BW, O’Fallon JR, Dozier JC, Piepgras DG (1993) Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg 78:741–747. doi:10.3171/jns.1993.78.5.0741
Pallini R, Maira G, Pierconti F, Falchetti ML, Alvino E, Cimino-Reale G, Fernandez E, D’Ambrosio E, Larocca LM (2003) Chordoma of the skull base: predictors of tumor recurrence. J Neurosurg 98:812–822. doi:10.3171/jns.2003.98.4.0812
Volpe R, Mazabraud A (1983) A clinicopathologic review of 25 cases of chordoma (a pleomorphic and metastasizing neoplasm). Am J Surg Pathol 7:161–170
Baratti D, Gronchi A, Pennacchioli E, Lozza L, Colecchia M, Fiore M, Santinami M (2003) Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 10:291–296
Jawad MU, Scully SP (2010) Surgery significantly improves survival in patients with chordoma. Spine (Phila Pa 1976) 35:117–123. doi:10.1097/BRS.0b013e3181b44387
Austin-Seymour M, Munzenrider J, Linggood R, Goitein M, Verhey L, Urie M, Gentry R, Birnbaum S, Ruotolo D, Crowell C et al (1990) Fractionated proton radiation therapy of cranial and intracranial tumors. Am J Clin Oncol 13:327–330
Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA, Rosenberg AE, Slater JM (1999) Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 91:432–439. doi:10.3171/jns.1999.91.3.0432
Ito E, Saito K, Okada T, Nagatani T, Nagasaka T (2009) Long-term control of clival chordoma with initial aggressive surgical resection and gamma knife radiosurgery for recurrence. Acta Neurochir (Wien). doi:10.1007/s00701-009-0535-7
Hasegawa T, Ishii D, Kida Y, Yoshimoto M, Koike J, Iizuka H (2007) Gamma Knife surgery for skull base chordomas and chondrosarcomas. J Neurosurg 107:752–757. doi:10.3171/JNS-07/10/0752
Martin JJ, Niranjan A, Kondziolka D, Flickinger JC, Lozanne KA, Lunsford LD (2007) Radiosurgery for chordomas and chondrosarcomas of the skull base. J Neurosurg 107:758–764. doi:10.3171/JNS-07/10/0758
Bjornsson J, Wold LE, Ebersold MJ, Laws ER (1993) Chordoma of the mobile spine. a clinicopathologic analysis of 40 patients. Cancer 71:735–740
Chandawarkar RY (1996) Sacrococcygeal chordoma: review of 50 consecutive patients. World J Surg 20:717–719
Choi D, Melcher R, Harms J, Crockard A Outcome of 132 operations in 97 patients with chordomas of the craniocervical junction and upper cervical spine. Neurosurgery 66: 59–65, discussion 65. doi:10.1227/01.NEU.0000362000.35742.3D
Wippold FJ 2nd, Koeller KK, Smirniotopoulos JG (1999) Clinical and imaging features of cervical chordoma. Am J Roentgenol 172:1423–1426
Colli BO, Al-Mefty O (2001) Chordomas of the skull base: follow-up review and prognostic factors. Neurosurg Focus 10:E1. doi:10.3171/foc.2001.10.3.2
Suster S, Moran CA (1995) Chordomas of the mediastinum: clinicopathologic, immunohistochemical, and ultrastructural study of six cases presenting as posterior mediastinal masses. Hum Pathol 26:1354–1362
Catton C, O’Sullivan B, Bell R, Laperriere N, Cummings B, Fornasier V, Wunder J (1996) Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 41:67–72
Chambers PW, Schwinn CP (1979) Chordoma. A clinicopathologic study of metastasis. Am J Clin Pathol 72:765–776
Cesinaro AM, Maiorana A, Annessi G, Collina G (1995) Cutaneous metastasis of chordoma. Am J Dermatopathol 17:603–605
Llauger J, Palmer J, Amores S, Bague S, Camins A (2000) Primary tumors of the sacrum: diagnostic imaging. Am J Roentgenol 174:417–424
Meyers SP, Hirsch WL Jr, Curtin HD, Barnes L, Sekhar LN, Sen C (1992) Chordomas of the skull base: MR features. Am J Neuroradiol 13:1627–1636
Almefty K, Pravdenkova S, Colli BO, Al-Mefty O, Gokden M (2007) Chordoma and chondrosarcoma: similar, but quite different, skull base tumors. Cancer 110:2457–2467. doi:10.1002/cncr.23073
Rossleigh MA, Smith J, Yeh SD (1986) Scintigraphic features of primary sacral tumors. J Nucl Med 27:627–630
Park SA, Kim HS (2008) F-18 FDG PET/CT evaluation of sacrococcygeal chordoma. Clin Nucl Med 33:906–908. doi:10.1097/RLU.0b013e31818c4e88
Zhang H, Yoshikawa K, Tamura K, Sagou K, Tian M, Suhara T, Kandatsu S, Suzuki K, Tanada S, Tsujii H (2004) Carbon-11-methionine positron emission tomography imaging of chordoma. Skeletal Radiol 33:524–530. doi:10.1007/s00256-004-0815-5
O’Connell JX, Renard LG, Liebsch NJ, Efird JT, Munzenrider JE, Rosenberg AE (1994) Base of skull chordoma. A correlative study of histologic and clinical features of 62 cases. Cancer 74:2261–2267
Naka T, Boltze C, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Kuester D, Roessner A (2003) Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer 98:1934–1941. doi:10.1002/cncr.11756
Cho HY, Lee M, Takei H, Dancer J, Ro JY, Zhai QJ (2009) Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma. Appl Immunohistochem Mol Morphol 17:131–138. doi:10.1097/PAI.0b013e3181866a13
Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, De Maglio G, den Bakker MA, Di Francesco L, Kalil RK, Athanasou NA, O’Donnell P, McCarthy EF, Flanagan AM (2008) Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol 32:572–580. doi:10.1097/PAS.0b013e31815b693a
Salisbury JR (1993) The pathology of the human notochord. J Pathol 171:253–255. doi:10.1002/path.1711710404
Henderson SR, Guiliano D, Presneau N, McLean S, Frow R, Vujovic S, Anderson J, Sebire N, Whelan J, Athanasou N, Flanagan AM, Boshoff C (2005) A molecular map of mesenchymal tumors. Genome Biol 6:R76. doi:10.1186/gb-2005-6-9-r76
Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, Boshoff C, Flanagan AM (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209:157–165. doi:10.1002/path.1969
Showell C, Binder O, Conlon FL (2004) T-box genes in early embryogenesis. Dev Dyn 229:201–218. doi:10.1002/dvdy.10480
Romeo S, Hogendoorn PC (2006) Brachyury and chordoma: the chondroid-chordoid dilemma resolved? J Pathol 209:143–146. doi:10.1002/path.1987
Park JB, Lee CK, Koh JS, Lee JK, Park EY, Riew KD (2007) Overexpressions of nerve growth factor and its tropomyosin-related kinase A receptor on chordoma cells. Spine (Phila Pa 1976) 32:1969–1973. doi:10.1097/BRS.0b013e318133fbb5
Yamaguchi T, Iwata J, Sugihara S, McCarthy EF Jr, Karita M, Murakami H, Kawahara N, Tsuchiya H, Tomita K (2008) Distinguishing benign notochordal cell tumors from vertebral chordoma. Skeletal Radiol 37:291–299. doi:10.1007/s00256-007-0435-y
Yamaguchi T, Suzuki S, Ishiiwa H, Ueda Y (2004) Intraosseous benign notochordal cell tumours: overlooked precursors of classic chordomas? Histopathology 44:597–602. doi:10.1111/j.1365-2559.2004.01877.x
Deshpande V, Nielsen GP, Rosenthal DI, Rosenberg AE (2007) Intraosseous benign notochord cell tumors (BNCT): further evidence supporting a relationship to chordoma. Am J Surg Pathol 31:1573–1577. doi:10.1097/PAS.0b013e31805c9967
Choi KS, Cohn MJ, Harfe BD (2008) Identification of nucleus pulposus precursor cells and notochordal remnants in the mouse: implications for disk degeneration and chordoma formation. Dev Dyn 237:3953–3958. doi:10.1002/dvdy.21805
Katoh Y, Katoh M (2005) Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther 4:1050–1054
Anton Aparicio LM, Garcia Campelo R, Cassinello Espinosa J, Valladares Ayerbes M, Reboredo Lopez M, Diaz Prado S, Aparicio Gallego G (2007) Prostate cancer and Hedgehog signalling pathway. Clin Transl Oncol 9:420–428
Hunter CJ, Matyas JR, Duncan NA (2003) The notochordal cell in the nucleus pulposus: a review in the context of tissue engineering. Tissue Eng 9:667–677. doi:10.1089/107632703768247368
Deniz ML, Kilic T, Almaata I, Kurtkaya O, Sav A, Pamir MN (2002) Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence. Neurosurgery 51:753–760, discussion 760
Bayrakli F, Guney I, Kilic T, Ozek M, Pamir MN (2007) New candidate chromosomal regions for chordoma development. Surg Neurol 68:425–430. doi:10.1016/j.surneu.2006.11.046 discussion 430
Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779–1802. doi:10.1016/j.clinthera.2006.11.015
Hallor KH, Staaf J, Jonsson G, Heidenblad M, Vult von Steyern F, Bauer HC, Ijszenga M, Hogendoorn PC, Mandahl N, Szuhai K, Mertens F (2008) Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer 98:434–442. doi:10.1038/sj.bjc.6604130
Brandal P, Bjerkehagen B, Danielsen H, Heim S (2005) Chromosome 7 abnormalities are common in chordomas. Cancer Genet Cytogenet 160:15–21. doi:10.1016/j.cancergencyto.2004.11.016
Almefty KK, Pravdenkova S, Sawyer J, Al-Mefty O (2009) Impact of cytogenetic abnormalities on the management of skull base chordomas. J Neurosurg 110:715–724. doi:10.3171/2008.9.JNS08285
Berven S, Zurakowski D, Mankin HJ, Gebhardt MC, Springfield DS, Hornicek FJ (2002) Clinical outcome in chordoma: utility of flow cytometry in DNA determination. Spine (Phila Pa 1976) 27:374–379
Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, Goldstein AM, Parry DM, Kelley MJ (2009) T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 41:1176–1178. doi:10.1038/ng.454
Shalaby AA, Presneau N, Idowu BD, Thompson L, Briggs TR, Tirabosco R, Diss TC, Flanagan AM (2009) Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Mod Pathol 22:996–1005. doi:10.1038/modpathol.2009.63
Klingler L, Trammell R, Allan DG, Butler MG, Schwartz HS (2006) Clonality studies in sacral chordoma. Cancer Genet Cytogenet 171:68–71. doi:10.1016/j.cancergencyto.2006.06.007
Longoni M, Orzan F, Stroppi M, Boari N, Mortini P, Riva P (2008) Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study. Neuro Oncol 10:52–60. doi:10.1215/15228517-2007-048
Riva P, Crosti F, Orzan F, Dalpra L, Mortini P, Parafioriti A, Pollo B, Fuhrman Conti AM, Miozzo M, Larizza L (2003) Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 107:493–497. doi:10.1002/ijc.11421
Scheil S, Bruderlein S, Liehr T, Starke H, Herms J, Schulte M, Moller P (2001) Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32:203–211. doi:10.1002/gcc.1184
Sommer J, Itani DM, Homlar KC, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Kelley MJ, Cates JM Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. J Pathol 220:608–617. doi:10.1002/path.2679
Robertson KD, Jones PA (1999) Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 18:3810–3820. doi:10.1038/sj.onc.1202737
Lubin M, Lubin A (2009) Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS One 4:e5735. doi:10.1371/journal.pone.0005735
Laguda B, Selden C, Jones M, Hodgson H, Spurr NK (1991) Assignment of the hepatocyte growth factor (HGF) to chromosome 7q22-qter. Ann Hum Genet 55:213–216
Liu X, Newton RC, Scherle PA (2009) Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. doi:10.1016/j.molmed.2009.11.005
Schwab JH, Boland PJ, Agaram NP, Socci ND, Guo T, O’Toole GC, Wang X, Ostroumov E, Hunter CJ, Block JA, Doty S, Ferrone S, Healey JH, Antonescu CR (2009) Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother 58:339–349. doi:10.1007/s00262-008-0557-7
Naka T, Kuester D, Boltze C, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A (2008) Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum Pathol 39:217–223. doi:10.1016/j.humpath.2007.06.005
Overall CM, Kleifeld O (2006) Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227–239. doi:10.1038/nrc1821
Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T (1999) MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 878:453–465
Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S (1994) Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2–23. Cancer Res 54:415–421
Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG, Pilotti S (2006) Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 12:6920–6928. doi:10.1158/1078-0432.CCR-06-1584
Fasig JH, Dupont WD, LaFleur BJ, Olson SJ, Cates JM (2008) Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. Neuropathol Appl Neurobiol 34:95–104. doi:10.1111/j.1365-2990.2007.00873.x
Weinberger PM, Yu Z, Kowalski D, Joe J, Manger P, Psyrri A, Sasaki CT (2005) Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 131:707–711. doi:10.1001/archotol.131.8.707
Naka T, Kuester D, Boltze C, Scheil-Bertram S, Samii A, Herold C, Ostertag H, Krueger S, Roessner A (2008) Expression of hepatocyte growth factor and c-MET in skull base chordoma. Cancer 112:104–110. doi:10.1002/cncr.23141
Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A (2009) EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol 22:1328–1340. doi:10.1038/modpathol.2009.104
Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, Diss T, Tirabosco R, Flanagan AM (2009) Potential therapeutic targets for chordoma: PI3 K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 100:1406–1414. doi:10.1038/sj.bjc.6605019
Singhal N, Kotasek D, Parnis FX (2009) Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs 20:953–955. doi:10.1097/CAD.0b013e328330c7f0
Hof H, Welzel T, Debus J (2006) Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 29:572–574. doi:10.1159/000096283
Linden O, Stenberg L, Kjellen E (2009) Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncol 48:158–159. doi:10.1080/02841860802266672
Rowinsky EK (2004) Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16:564–575
MacKenzie AR, von Mehren M (2007) Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future. Expert Rev Anticancer Ther 7:1145–1154. doi:10.1586/14737140.7.8.1145
Lee-Jones L, Aligianis I, Davies PA, Puga A, Farndon PA, Stemmer-Rachamimov A, Ramesh V, Sampson JR (2004) Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2. Genes Chromosomes Cancer 41:80–85. doi:10.1002/gcc.20052
Borgel J, Olschewski H, Reuter T, Miterski B, Epplen JT (2001) Does the tuberous sclerosis complex include clivus chordoma? A case report. Eur J Pediatr 160:138
Kimmell KT, Dayoub H, Stolzenberg ED, Sincoff EH Chordoma in the lateral medullary cistern in a patient with tuberous sclerosis: a case report and review of the literature. Surg Neurol Int 1: 13. doi:10.4103/2152-7806.63908
Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926–1945. doi:10.1101/gad.1212704
Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, Crippa F, Morosi C, Gronchi A, Pilotti S, Casali PG (2009) Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 20:1886–1894. doi:10.1093/annonc/mdp210
Schwab J, Antonescu C, Boland P, Healey J, Rosenberg A, Nielsen P, Iafrate J, Delaney T, Yoon S, Choy E, Harmon D, Raskin K, Yang C, Mankin H, Springfield D, Hornicek F, Duan Z (2009) Combination of PI3 K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res 29:1867–1871
Yang C, Schwab JH, Schoenfeld AJ, Hornicek FJ, Wood KB, Nielsen GP, Choy E, Mankin H, Duan Z (2009) A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther 8:2597–2605. doi:10.1158/1535-7163.MCT-09-0504
Jawad MU, Scully SP (2010) Surgery significantly improves survival in patients with chordoma. Spine (Phila Pa 1976) 35:117–123. doi:10.1097/BRS.0b013e3181b44387
Schwab JH, Healey JH, Rose P, Casas-Ganem J, Boland PJ (2009) The surgical management of sacral chordomas. Spine (Phila Pa 1976) 34:2700–2704. doi:10.1097/BRS.0b013e3181bad11d
Hsieh PC, Xu R, Sciubba DM, McGirt MJ, Nelson C, Witham TF, Wolinksy JP, Gokaslan ZL (2009) Long-term clinical outcomes following en bloc resections for sacral chordomas and chondrosarcomas: a series of twenty consecutive patients. Spine (Phila Pa 1976) 34:2233–2239. doi:10.1097/BRS.0b013e3181
Tzortzidis F, Elahi F, Wright DC, Temkin N, Natarajan SK, Sekhar LN (2006) Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chondrosarcomas. Neurosurgery 58:1090–1098. doi:10.1227/01.NEU.0000215892.65663.54 discussion 1090–1098
Boriani S, Bandiera S, Biagini R, Bacchini P, Boriani L, Cappuccio M, Chevalley F, Gasbarrini A, Picci P, Weinstein JN (2006) Chordoma of the mobile spine: fifty years of experience. Spine (Phila Pa 1976) 31:493–503. doi:10.1097/01.brs.0000200038.30869.27
Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, Schuller JC, Pedroni E, Goitein G (2009) Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys 75:1111–1118. doi:10.1016/j.ijrobp.2008.12.055
Noel G, Feuvret L, Calugaru V, Dhermain F, Mammar H, Haie-Meder C, Ponvert D, Hasboun D, Ferrand R, Nauraye C, Boisserie G, Beaudre A, Gaboriaud G, Mazal A, Habrand JL, Mazeron JJ (2005) Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol 44:700–708. doi:10.1080/02841860500326257
Henderson FC, McCool K, Seigle J, Jean W, Harter W, Gagnon GJ (2009) Treatment of chordomas with CyberKnife: georgetown university experience and treatment recommendations. Neurosurgery 64:A44–A53. doi:10.1227/01.NEU.0000341166.09107.47
Durante M, Loeffler JS (2010) Charged particles in radiation oncology. Nat Rev Clin Oncol 7:37–43. doi:10.1038/nrclinonc.2009.183
Ostroumov E, Hunter CJ (2007) The role of extracellular factors in human metastatic chordoma cell growth in vitro. Spine (Phila Pa 1976) 32:2957–2964. doi:10.1097/BRS.0b013e31815cde91
Schulz-Ertner D, Karger CP, Feuerhake A, Nikoghosyan A, Combs SE, Jakel O, Edler L, Scholz M, Debus J (2007) Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 68:449–457. doi:10.1016/j.ijrobp.2006.12.059
Sonveaux P, Brouet A, Havaux X, Gregoire V, Dessy C, Balligand JL, Feron O (2003) Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 63:1012–1019
Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, Leu KM, Chandler WF, Baker LH (2005) Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 23:3597–3604. doi:10.1200/JCO.2005.02.170
Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S (2004) Imatinib mesylate in chordoma. Cancer 101:2086–2097. doi:10.1002/cncr.20618
FV StacchiottiS, Ferraresi G, Grignani F, Crippa A, Messina E, Tamborini CS, Gronchi A, Casali PG (2007) Imatinib mesylate in advanced chordoma: a multicenter phase II study. J Clin Oncol 25:10003
Orzan F, Terreni MR, Longoni M, Boari N, Mortini P, Doglioni C, Riva P (2007) Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas. Oncol Rep 18:249–252
Ferraresi V, Nuzzo C, Zoccali C, Marandino F, Vidiri A, Salducca N, Zeuli M, Giannarelli D, Cognetti F, Biagini R (2010) Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer 10:22. doi:10.1186/1471-2407-10-22
Casali PG, Stacchiotti S, Grosso F, Messina A, Crippa F, Tamborini E, Bertieri R, Collini P, Pilotti S, Gronchi A (2007) Adding cisplatin (CDDP) to imatinib (IM) re-establishes tumor response following secondary resistance to IM in advanced chordoma. 2007 ASCO Annual Meeting Proceedings Part I, Vol 25, No. 18S. J Clin Oncol(June 20 Suppl):10038
Stacchiotti S, Grosso F, Dileo P et al (2006) Antitumor activity of imatinib plus cisplatin in two patients with advanced chordoma. In: Proceedings of 12th Annual Connective Tissue Oncology Society Meeting 2006, 58 (Abstr 725)
Fleming GF, Heimann PS, Stephens JK, Simon MA, Ferguson MK, Benjamin RS, Samuels BL (1993) Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 72:714–718
Scimeca PG, James-Herry AG, Black KS, Kahn E, Weinblatt ME (1996) Chemotherapeutic treatment of malignant chordoma in children. J Pediatr Hematol Oncol 18:237–240
Azzarelli A, Quagliuolo V, Cerasoli S, Zucali R, Bignami P, Mazzaferro V, Dossena G, Gennari L (1988) Chordoma: natural history and treatment results in 33 cases. J Surg Oncol 37:185–191
Guiu S, Guiu B, Feutray S, Chauffert B (2009) Direct intratumoral chemotherapy with carboplatin and epinephrine in a recurrent cervical chordoma: case report. Neurosurgery 65:E629–E630. doi:10.1227/01.NEU.0000350864.78326.14 discussion E630
Parr C, Sanders AJ, Jiang WG (2009) Hepatocyte growth factor activation inhibitors—therapeutic potential in cancer. Anticancer Agents Med Chem 10:47–57
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207–2214. doi:10.1158/1078-0432.CCR-08-1306
Keisch ME, Garcia DM, Shibuya RB (1991) Retrospective long-term follow-up analysis in 21 patients with chordomas of various sites treated at a single institution. J Neurosurg 75:374–377. doi:10.3171/jns.1991.75.3.0374
Boriani S, Chevalley F, Weinstein JN, Biagini R, Campanacci L, De Iure F, Piccill P (1996) Chordoma of the spine above the sacrum treatment and outcome in 21 cases. Spine (Phila Pa 1976) 21:1569–1577
al-Mefty O, Borba LA (1997) Skull base chordomas: a management challenge. J Neurosurg 86:182–189. doi:10.3171/jns.1997.86.2.0182
York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, Gokaslan ZL (1999) Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 44:74–79 discussion 79–80
Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom JM (2000) Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 88:2122–2134. doi:10.1002/(SICI)1097-0142(20000501)88:9<2122:AID-CNCR19>3.0.CO;2-1
Carpentier A, Polivka M, Blanquet A, Lot G, George B (2002) Suboccipital and cervical chordomas: the value of aggressive treatment at first presentation of the disease. J Neurosurg 97:1070–1077. doi:10.3171/jns.2002.97.5.1070
Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH (2005) Operative management of sacral chordoma. J Bone Joint Surg Am 87:2211–2216. doi:10.2106/JBJS.D.02693
Tzortzidis F, Elahi F, Wright D, Natarajan SK, Sekhar LN (2006) Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 59:230–237. doi:10.1227/01.NEU.0000223441.51012.9D discussion 230–237
Samii A, Gerganov VM, Herold C, Hayashi N, Naka T, Mirzayan MJ, Ostertag H, Samii M (2007) Chordomas of the skull base: surgical management and outcome. J Neurosurg 107:319–324. doi:10.3171/JNS-07/08/0319
Takahashi S, Kawase T, Yoshida K, Hasegawa A, Mizoe JE (2009) Skull base chordomas: efficacy of surgery followed by carbon ion radiotherapy. Acta Neurochir (Wien) 151:759–769. doi:10.1007/s00701-009-0383-5
Jian BJ, Bloch OG, Yang I, Han SJ, Aranda D, Tihan T, Parsa AT (2010) Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. J Neurooncol 98:101–108. doi:10.1007/s11060-009-0068-1
Choi D, Melcher R, Harms J, Crockard A (2010) Outcome of 132 operations in 97 patients with chordomas of the craniocervical junction and upper cervical spine. Neurosurgery 66:59–65. doi:10.1227/01.NEU.0000362000.35742.3D discussion 65
Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, Gronchi A, Picci P (2010) Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 17:211–219. doi:10.1245/s10434-009-0740-x
Ruggieri P, Angelini A, Ussia G, Montalti M, Mercuri M (2010) Surgical margins and local control in resection of sacral chordomas. Clin Orthop Relat Res 468:2939–2947. doi:10.1007/s11999-010-1472-8
Wu Z, Zhang J, Zhang L, Jia G, Tang J, Wang L, Wang Z (2010) Prognostic factors for long-term outcome of patients with surgical resection of skull base chordomas-106 cases review in one institution. Neurosurg Rev 33:451–456. doi:10.1007/s10143-010-0273-6
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Diaz, R.J., Cusimano, M.D. The biological basis for modern treatment of chordoma. J Neurooncol 104, 411–422 (2011). https://doi.org/10.1007/s11060-011-0559-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-011-0559-8